Effectiveness of ethylmethylhydroxypyridine succinate in alcohol withdrawal

BACKGROUND: Alcohol (ethanol) use disorder is a destructive condition with alterations in impaired energy and metabolic processes and activation of free radical oxidation processes. Therefore, the use of antioxidants in the complex therapy of this pathology is pathogenetically justified, one of which is the original domestic drug ethylmethylhydroxypyridine succinate.

AIM: To examine the effectiveness of ethylmethylhydroxypyridine succinate in intravenous, intramuscular, and intragastric methods of administration to male ICR mice in modeling alcohol withdrawal.

MATERIALS AND METHODS: The study was performed on 9- to 10-week-old male specific pathogen-free mice of the ICR outflow with an average weight of 25.4 ± 0.2 g. Alcohol dependence in animals was modeled by a gradual increase in ethanol in the drinker from 1% to 3%, 6%, and 10% every 2 days. Upon reaching a concentration of 10%, the animals were given one bottle of alcohol and one bottle of water every other day and two bottles of alcohol on intermediate days. The position of the bottles (left/right) was changed between each alcohol access session. After 6 weeks, 10% alcohol was removed. The administration of ethylmethylhydroxypyridine succinate and saline solution (control group) was started twice a day for 7 days. Ethylmethylhydroxypyridine succinate was administered intravenously (50 and 100 mg/kg), intramuscularly (50 and 100 mg/kg), and intragastrically (100 and 150 mg/kg).

RESULTS: Ethylmethylhydroxypyridine succinate was administered intravenously (50 and 100 mg/kg), intramuscularly (50 and 100 mg/kg), and intragastrically (100 and 150 mg/kg) two times a day for 7 days resulted in the manifestations of alcohol withdrawal in ICR mice with alcohol dependence. It had pronounced pharmacological activity, which manifested in a decrease in alcohol consumption, improvement of horizontal and vertical activities, improvement of movement coordination, and a decrease in the severity of withdrawal syndrome detected in the nesting ability test.

CONCLUSION: When administered intravenously (50 and 100 mg/kg), intramuscularly (50 and 100 mg/kg), and intragastrically (100 and 150 mg/kg) to male mice, ICR had a pronounced therapeutic effect in modeling alcohol withdrawal.